Bioequivalence and the pharmaceutical industry
- 1 December 2002
- journal article
- research article
- Published by Wiley in Pharmaceutical Statistics
- Vol. 1 (2), 83-95
- https://doi.org/10.1002/pst.15
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Limits of 80% – 125% for AUC and 70% – 143% for Cmax. What is the impact on bioequivalence studies?International journal of clinical pharmacology and therapeutics, 2001
- Evaluation of the Bioequivalence of Highly-Variable Drugs and Drug ProductsPharmaceutical Research, 2001
- Case studies, practical issues and observations on population and individual bioequivalenceStatistics in Medicine, 2000
- PhRMA Perspective on Population and Individual BioequivalenceThe Journal of Clinical Pharmacology, 2000
- Statistical and Regulatory Considerations for Multiple Measures in Bioequivalence TestingClinical Research and Regulatory Affairs, 1995
- An Approach for Widening the Bioequivalence Acceptance Limits in the Case of Highly Variable DrugsPharmaceutical Research, 1995
- Consideration of individual bioequivalenceJournal of Pharmacokinetics and Biopharmaceutics, 1990
- Design and Analysis of Cross-Over TrialsPublished by Informa UK Limited ,1989
- A comparison of the Two One-Sided Tests Procedure and the Power Approach for assessing the equivalence of average bioavailabilityJournal of Pharmacokinetics and Biopharmaceutics, 1987
- A new procedure for testing equivalence in comparative bioavailability and other clinical trialsCommunications in Statistics - Theory and Methods, 1983